Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) – Pipeline Review, H1 2017’, provides in depth analysis on Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Musculoskeletal Disorders, Immunology, Central Nervous System, Gastrointestinal, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Respiratory and Undisclosedunder development targeting Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AB Science SA

Amgen Inc

Array BioPharma Inc

BCI Pharma

Bristol-Myers Squibb Company

Cielo Therapeutics Inc

CrystalGenomics Inc

CTI BioPharma Corp

Deciphera Pharmaceuticals LLC

Eli Lilly and Company

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

Hutchison China MediTech Ltd

Ignyta Inc

Johnson & Johnson

Nerviano Medical Sciences Srl

Novartis AG

Pfizer Inc

Plexxikon Inc

Redx Pharma Plc

SignalChem Lifesciences Corp

Syndax Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Overview

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Companies Involved in Therapeutics Development

AB Science SA

Amgen Inc

Array BioPharma Inc

BCI Pharma

Bristol-Myers Squibb Company

Cielo Therapeutics Inc

CrystalGenomics Inc

CTI BioPharma Corp

Deciphera Pharmaceuticals LLC

Eli Lilly and Company

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

Hutchison China MediTech Ltd

Ignyta Inc

Johnson & Johnson

Nerviano Medical Sciences Srl

Novartis AG

Pfizer Inc

Plexxikon Inc

Redx Pharma Plc

SignalChem Lifesciences Corp

Syndax Pharmaceuticals Inc

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Drug Profiles

AMG-820 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-382 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLZ-945 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabiralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCC-3014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELB-041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emactuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-2580 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-28312141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-40346527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3022855 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMS-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pacritinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride + pembrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-0360324 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexidartinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-73086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibitor CSF1R for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CSF-1 Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CSF-1R for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FMS for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target CSF-1R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNDX-6352 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Dormant Products

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Discontinued Products

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC

2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jun 04, 2017: Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting

May 31, 2017: Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT (Sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery

May 18, 2017: Chi-Med Presents Clinical Data on Sulfatinib at ASCO 2017 Annual Meeting

May 18, 2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib)

May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting

May 17, 2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings

May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards

Apr 20, 2017: Five Prime to Present Clinical Data on cabiralizumab at 2017 ASCO Annual Meeting

Apr 10, 2017: Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis

Apr 07, 2017: Chi-Med Presented Pre-clinical Data for Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

Apr 03, 2017: Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting

Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years

Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib)

Mar 20, 2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis

Mar 10, 2017: Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1)

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by AB Science SA, H1 2017

Pipeline by Amgen Inc, H1 2017

Pipeline by Array BioPharma Inc, H1 2017

Pipeline by BCI Pharma, H1 2017

Pipeline by Bristol-Myers Squibb Company, H1 2017

Pipeline by Cielo Therapeutics Inc, H1 2017

Pipeline by CrystalGenomics Inc, H1 2017

Pipeline by CTI BioPharma Corp, H1 2017

Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Pipeline by Eli Lilly and Company, H1 2017

Pipeline by Elsalys Biotech SAS, H1 2017

Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Pipeline by Hutchison China MediTech Ltd, H1 2017

Pipeline by Ignyta Inc, H1 2017

Pipeline by Johnson & Johnson, H1 2017

Pipeline by Nerviano Medical Sciences Srl, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Pfizer Inc, H1 2017

Pipeline by Plexxikon Inc, H1 2017

Pipeline by Redx Pharma Plc, H1 2017

Pipeline by SignalChem Lifesciences Corp, H1 2017

Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Dormant Products, H1 2017 (Contd..2), H1 2017

Dormant Products, H1 2017 (Contd..3), H1 2017

Dormant Products, H1 2017 (Contd..4), H1 2017

Discontinued Products, H1 2017

Discontinued Products, H1 2017 (Contd..1), H1 2017

Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports